

For in vitro diagnostic use



# APO-E (ARG158CYS) C4070T POLYMORPHISM

#### ORDERING INFORMATIONS

REF: GEN-009-25 RDM Code: 2255495/R Tests: 25 Reactions: 31 REF: GEN-009-50 RDM Code: 1735882/R Tests: 50 Reactions: 62 CND Code: W0106010499 Manufacturer: BioMol Laboratories s.r.l.

### CONTENTS OF THE KIT

The kit consists of reagents for Real-Time PCR amplification \*reagents for the extraction of genomic DNA are not supplied in the kit

### PRODUCT CHARACTERISTICS

Device belonging to the family of in vitro medical devices REAL-TIME QUALITATIVE PCR -GENETIC VARIANTS. Detection of C4070T polymorphism (called R158C, ARG158CYS) of the APO-E gene by Real-Time PCR technique. Optimized kit for Real-Time PCR instrumentation Biorad CFX96, Biorad Opus DX, Agilent AriaDx, Hyris bCUBE e Hyris bCUBE3 with Hyris bAPP.

#### SCIENTIFIC BACKGROUND

The genetic origin of the three variants of the human apolipoprotein E (apoE) protein, known as E2, E3, and E4, was understood in 1981. The underlying genetic variants of these protein isoforms, known as  $\epsilon_2$ ,  $\epsilon_3$ , and  $\epsilon$ 4, are allelic forms of the APOE gene, resulting from different haplotypes at the APOE locus (19q13.31). In particular, APOE is polymorphic with three main alleles (e2, e3 and e4): APOE-ɛ2 (cys112, cys158), APOE- $\epsilon$ 3 (cys112, arg158) and APOE- $\epsilon$ 4 (arg112, arg158). Although these allelic forms differ from each other by only one or two amino acids at positions 112 and 158, these differences alter the structure and function of APOF

apoE N-terminus			LDLR Binding Region		apoE C-terminus Lipid Binding Region		
He	tox 1 H11 Helix 2	Helix 3	Helix 4	=(			
	Disease Risk	Isoform-Specific			Allelic Frequency		
	Association	Amino Aci	d Differences		ε2	23	ε4
apoΕ ε <b>2</b>	Hyperlipoproteinemia Atherosclerosis	cys 112	cys 158	ε2	1-2%	~15%	1-2%
apoE 23	Disease Neutral	cys 112	arg 158	23		~55%	~25%
apoE ε4	Alzheimer's Disease Atherosclerosis	arg 112	arg 158	ε4		[	1-2%

 $<sup>\</sup>pmb{S}$  Meta-analysis: BMC Neurosci. 2024 Jun 25;25()):28. Diabetes mellitus and risk of incident dementia in APOE  $_{e4}$  carriers: an updated meta-analysis

§ The APOE E4 Allele Conters Increased Risk of Ischemic Stroke Among Greek Carriers. Adv Clin Exp Med. 2016 May-Jun; 25 (3):471-8.
§ Plasma levels of apolipoprotein E, APOE genotype and risk of dementia and ischemic heart disease: A review Atherosclerosis. 2016 Dec; 255: 145-155.
§ Genetics of healthy aging and longevity. Hum Genet. 2013 Dec; 132 12):1323-38.
§ APOE epsilon 4 allele predicts faster cognitive decline in mild Alzheimer disease. Neurology 70: 1842–1849. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, et al. (2008).

### CLINICAL SIGNIFICANCE

The combination of the various polymorphisms is responsible for some risk conditions:

- ε2 (rs7412-T, rs429358-T) has an allele frequency of about 7%. This apolipoprotein variant binds poorly to cell surface receptors while E3 and E4 bind well. Individuals with an e2/e2 combination may have an increased risk of early vascular disease. The e2 allele has also been implicated in Parkinson's disease.

- ε3 (rs7412-C, rs429358-T) has an allele frequency of approximately 79%. It is considered the "neutral" Apo E genotype.

- ε4 (rs7412-C, rs429358-C) has an allele frequency of approximately 14%.  $\epsilon 4$  has been implicated in atherosclerosis, Alzheimer's disease, decreased cognition, decreased hippocampal volume, time to disease progression in multiple sclerosis, poor outcome after traumatic brain injury, cerebrovascular disease ischemia, sleep apnea, telomere shortening, and impaired neurite outgrowth.

There are two forms of Alzheimer's disease (AD): the rare, early-onset (familial) and the common, lateonset (sporadic) forms. Late-onset AD accounts for approximately 95% of AD cases and is not caused by mutations in single genes. However, the epsilon-4 variant of the apolipoprotein E gene (APOE) has been shown to have deleterious effects on both the lifetime risk and age of onset of the disease.



**BIOMOL LABORATORIES S.R.L.** Via Arcora 110 (Palazzo Gecos) 80013 Casalnuovo di Napoli, NA info@biomollaboratories.com biomollaboratories.it

ISO 9001 :2015 ISO 13485:2021

S Meta-analysis: Behav Brain Res. 2024 Aug 5471:115123. Cognitive deficits in human ApoE4 knock-in mice: A systematic review and meta-analysis § Meta-analysis: J Alzheimers Dis. 2023;35(3):1095-109. Meta-Analysis of Variations in Association between APOE 4 and Alzheimer's Disease and Related Dementias Across Viewers 0. Portange 46 Onic 4 and Alzheimer's Disease and Related Dementias Across

Hispanic Regions of Origin § The APOE E4 Allele Confers Increased Risk of Ischemic Stroke Among Greek Carriers.



For in vitro diagnostic use



# APO-E (ARG158CYS) C4070T POLYMORPHISM

# ORDERING INFORMATIONS

REF: GEN-009-25 RDM Code: 2255495/R Tests: 25 Reactions: 31 REF: GEN-009-50 RDM Code: 1735882/R Tests: 50 Reactions: 62 CND Code: W0106010499 Manufacturer: BioMol Laboratories s.r.l.

## CONTENTS OF THE KIT

The kit consists of reagents for Real-Time PCR amplification \*reagents for the extraction of genomic DNA are not supplied in the kit

## CONTENTS OF THE KIT

DESCRIPTION	LABEL	VOLUME		STORAGE
		GEN-009-25	GEN-009-50	
Mix oligonucleotides and probes	Mix C4070T APO-E 10X	1 x 77,5 µl	2 x 77,5 µl	-20°C
Mix buffer and Taq polymerase enzyme	Mix Real-Time PCR 2X	1 x 387,5 µl	2 x 387,5 µl	-20°C
Deionized H <sub>2</sub> O	Deionized H <sub>2</sub> O	1x1ml	1x1ml	-20°C
Genomic DNA or recombinant DNA	Control 1	1 x 22 µl	2 x 22 µl	-20°C
Genomic DNA or recombinant DNA	Control 2	1 x 22 µl	2 x 22 µl	-20°C
Genomic DNA or recombinant DNA	Control 3	1 x 22 µl	2 x 22 µl	-20°C

# TECHNICAL CHARACTERISTICS

## COD. GEN-009-25 / COD. GEN-009-50

STABILITY	18 months			
REAGENTS STATUS	Ready to use			
BIOLOGICAL MATRIX	Genomic DNA extracted from whole blood, tissue, cells			
CONTROLS	Recombinant DNA for at least 3 analytical sessions (GEN-009-25) Recombinant DNA for at least 6 analytical sessions (GEN-009-50)			
VALIDATED INSTRUMENTS	Biorad CFX96 Dx, Biorad Opus Dx and Agilent AriaDx, Hyris bCUBE, Hyris bCUBE3 with Hyris bAPP.			
TECHNOLOGY	Real-time PCR; oligonucleotides and specific probes; 2 FAM/HEX fluorescence channels			
RUNNING TIME	85 min			
THERMAL CYCLING PROFILE	l cycle at 95 °C (10 min); 45 cycles at 95 °C (15 sec) + 60 °C (60 sec			
ANALYTICAL SPECIFICITY	Absence of non-specific pairings of oligonucleotides and probes; absence of cross-reactivity			
LIMIT OF DETECTION (LOD)	≥ 0,016 ng of genomic DNA			
LIMIT OF BLANK (LOB)	0% NCN			
REPRODUCIBILITY	99,9%			
DIAGNOSTIC SPECIFICITY / DIAGNOSTIC SENSITIVITY	100%/98%			

BIOMOL LABORATORIES S.R.L Via Arcora 110 (Palazzo Gecos) 80013 Casalnuovo di Napoli, NA info@biomollaboratories.com biomollaboratories.it ISO 9001 :2015 ISO 13485:2021

